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CYCLOSPORINE PHARMACOKINE-Tl CS has been described in patients 
followi ng kid ney, liver, heart, and bone mar-
row transplantation. 1 Many of these studies 
have been performed using high-performance 
liquid chromatography (HPLC) because of its 
specificity for cyclosporine (Cs). Even using a 
s;,ecific assay, the results of these pharmaco-
kinetic studies are difficult to interpret due to 
the complex natures of the drug and of trans-
plant patients. Similar studies of comparative 
groups of subjects must be performed to per-
mit the proper understanding of the effect of 
the disease state and the transplant operation 
on the disposition of Cs. This article, there-
fore, briefly reviews the HPLC assay of Cs, 
presents Cs kinetic profiles by HPLC on both 
nontransplant comparative groups and trans-
plant patients, and discusses the interpreta-
tion of differences between transplant groups 
and comparative groups. 
HPLC ASSAY 
Several HPLC procedures are available to 
measure Cs in biological fluids and are sum-
marized in Table 1. HPLC procedures require 
extensive sample extraction or a column-
selective isolation technique. The latter proce-
dure requires specialized instrumentation not 
commonly available in all laboratories. The 
extraction of Cs from biological fluids involves 
solid-liquid or liquid-liquid extraction meth-
ods. In the solid-liquid method, Cs is sepa-
rated from endogenous substances using col-
umns such as Baker cyano columns.9•12 In the 
liquid-liquid extraction method, Cs is ex-
tracted with ether. In some procedures, fur-
ther sample purification is carried out using 
haxane. H 
The isolated Cs can be chromatographed 
using a C-18 or cyano column maintained at a 
temperature of 55°C to 75 0c. The mobile 
phase generally consists of various combina-
tions of acetonitrile, methanol, and water. Cs 
and CsD (internal standard) usually elute 
within 12 minutes. After liquid-liquid extrac-
tion procedures, late peaks (possibly phthal-
ates) may occasionally lengthen the chroma-
tography time to as long as 25 to 30 minutes. 
HPLC is specific for unchanged Cs and is 
sensitive to concentrations as low as 25 ng/ 
mL using 1 mL of blood. HPLC is linear over 
the range of 25 to 4,000 ng/mL and is useful 
for the analysis of blood, bile, plasma, serum, 
urine, cerebrospinal fluid (CSF), and breast 
milk. The HPLC methodology is easily 
adapted to measure metabolites of CSl4 and 
other immunosuppressive compounds specifi-
cally, and we now use an HPLC method for 
the determination of CsG using Cs as the 
internal standard. IS 
Cs monitoring and pharmacokinetic studies 
have been performed using whole blood, 
serum, and plasma. The concentrations of Cs 
in blood are approximately twice those mea-
sured in plasma, which reflects the extensive 
distribution of Cs into erythrocytes. 16•17 The 
relative distribution of Cs between blood cells 
and plasma depends on several factors, includ-
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Table 1. HPLC Assays to Quantitate Cyclosporine Biological Fluids 
Minimum 
Mode of ae~tion 
Sample Preparation Column/Conditions Analysis Mobile Phase (')6) Limit (ng) 
Serum' 5-L j.LBondapak C-18*; Isocratic M/W (95/5) 100 
55 ·C 
Plasma' L-L Ultrasphereoctylt; Isocratic A/W/M (47/20/33) 31 
72 'c 
Blood and plasma' L-L j.LBondapak C-l 8· ; Gradient I/H (14/86 to 36/64) 100 
25 ·C in 30 min 
Plasma" 5-L Zorbax TMSt; 55 ·C Isocratic A/W(60/40) 100 
Plasma and urine" L-L Lichrosorb RP-B§; Gradient A/W/M (20/60/20 to 25 
72 'c 75/5/20) in 26 min 
Plasma and blood7 PP Lichrosorb C-l B§; Column switching 6 Solvent-switching 20 
70 ·C scheme with step 
gradient 
Plasma and bloods L-L Supelcosil LC-1811; Isocratic A/W (68.5/31.5) 25 
75 'c 
Serum" 5-L Ultrasphere OOSt; Gradient· A/W (35/65 to 5/15) 50 
70 'c at 15 min 
Plasma and blood'· Supelcosil LC-811; 
w' ........ 
PP Column switching A/W (55/45 switched 8 (plasma); 20 
75 'c to 75/25) (blood) 
Plasma, serum, and S-L Zorbax Cyanopro- Isocratic A/W(51/49) 10-15 
bloodt1 pyl~; 58 ·C 
Serum and blood" S-L Brown Lee RP-811; Isocratic A/W(72/28) <50 
70 'c 
Plasma" L-L Lichrosorb RP-8§; Isocratic M/W(83/17) 2 
73 'c 
Abbreviations: S-L, solid-liquid extraction; L-L, liquid-liquid extraction; PP, Protein Precipitation; M. methanol; W. water; A. 
acetonitrile; I. isopropanol; H. Heptane. ·Waters, Milford, MA; tAltex Division, Beckman Instruments Inc, San Ramon. CA; 
~aumontI Wilmington, DE; §EM Industries Inc, Hawthorne, NY; Ijsupelco Inc, Bellefonte, PA; lIBrownlee, Santa Clara, CA. 
ing the temperature of separation of plasma 
from erythrocytes, the patient's hematocrit, 
the drug concentration, and the lipoprotein 
content and composition in patient plasma. 
Plasma samples separated at room tempera-
ture have up to 50% lower Cs concentrations 
than samples separated at 37 oc. I8-20 The tem-
perature-dependent concentration of Cs in 
plasma is due to altered red blood cell and 
lipoprotein uptake of Cs at different tempera-
tures. The optimal temperature for separation 
of plasma from blood for obtaining physiologi-
cally meaningful pharmacokinetic parameter 
estimates is 37 °C in order to simulate in vivo 
Cs distribution in blood. Since the tempera-
ture-dependent Cs distribution is reversible, 
samples stored at <37°C can be reequili-
bra ted at 37°C for plasma separation. This 
approach should be used for pharmacokinetic 
studies but may be impractical for routine 
clinical monitoring. Since the concentration of 
Cs in plasma is lower than that in the blood, 
there tends to be a greater variability in Cs 
estimations in plasma as compared with whole 
blood,21 . 
Pharmacokinetic parameters that are based 
on the absolute quantity of Cs in the speci-
men, such as clearance and volume of distri-
bution, may therefore vary depending 
whether blood or plasma or serum was used. 
Nontransplant Patient Studies 
Cyclosporine has been administered to 
several groups of patients who have not under-
gone solid organ or bone marrow transplanta-
tion. These studies provide a valuable compar-
ative group for interpreting changes in the 
pharmacokinetic profiles in transplant pa-
tients. Table 2 lists the half-life (t 1/ 2), the total 
body clearance (CL), the steady state volume 
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Table 2. HPLC Cyclosporine Kinetic Parameters in Nontransplant Studies 
Study Dosing 
Number of Biological 
Patient Population Subjects Fluid 
Healthy volunteers" 5 Siood 
Patients with renal fail- 4 Blood 
ure23 
Uremic patients" 21 Blood 
Patients with liver failure" S Siood 
Patients with liver dis- 9 Serum 
easelS 
Pediatric patients with 5 Blood 
congestive heart fail-
ure26 
"Unpublished observations. 
tAssuming 70 kg body weight. 
of distribution (V d), and the fraction of an 
oral dose that was absorbed (F) for Cs in 
non transplant patients. This information 
should expand considerably over the next few 
years as the use of Cs in autoimmune disease 
broadens. 
Transplant Patient Studies 
Table 3 summarizes the studies performed 
utilizing HPLC in transplant patient groups. 
Interval t1/.2 
(hi (hi 
48 6.2 
(4.7-9.5) 
48 15.8 
I±S.4) 
48 12.2 
(6.4-26.9) 
4S 20.4 
110.8-48) 
20 8.7 
(±3.3) 
24 7.5 
(±2.1) 
CL 
(mL/min/kg) 
3.9 
12.9-5.5) 
5.9 
(±1.4) 
5.1t 
(±1.4) 
2.8 
(1.9-4.8) 
30.4 
I± 15.5) 
1.9 
(±O.3) 
Vd 
(L/kg) 
1.3 
(±0.3) 
3.5 
(±2.7) 
8.6 
(±5.1) 
3.9 
(± 1.8) 
13.8 
(± 11.2) 
0.9 
(±O.2) 
F 
(%) 
38 
(± 17) 
11.9 
24.4 
(n - 1) 
Most of the studies have used whole blood Cs 
concentrations; but those using serum have 
performed the separation of blood and serum 
at room temperature. 
DISCUSSION 
An examination of Tables 2 and 3 point out 
some important differences between trans-
plant patients and either healthy volunteers or 
patients with renal, liver, or cardiac disease. 
Table 3. HPLC Cyclosperinll Kinetic Parameters in Transplant Patient Studies 
Study Dosing 
Number of Biological Interval t"" CL Vd F 
Patient Population Subjects Fluid (h) (h) (mL/min/kg) (L/kg) ('J6) 
Renal transplant patients" 11 Blood 48 4.6 9.2 41 
(±1.3) (±3.2) (± 15) 
Bane marrow transplant 10 Serum 12 6.7 12.8 4.3 
serum bilirubin < 1 .2 (±1.6) (± 1.6) (±O.9) 
mg/dL 27 
Bone marrow transplant 11 'Serum 12 12.7 9.8 3.5 
serum bilirubin <2.0 (±6.1) (±2.1) (± 1.1) 
mg/dL'7 
Adult renal transplant pa- 41 Blood 24 10.7 5.7 4.5 28 
tients2• (4.3-53.4) (0.6-23.9) (±3.6) 1±21) 
Pediatric renal transplant 7 Blood 12-24 7.3 11.8 4.7 31 
patients29 (6.1-16.6) (9.8-15.5) (± 1.5) (±10) 
Adult liver transplant pa- 6 Blood 12 5.5 27 
tients'o (4.9-7.6) (8-60) 
Pediatric liver transplant 26 ' Blood 8 8.4 <5-19 
patients" (1.9-13.9) 
Heart transplant patients" 4 Blood 12 6.4 4.0 1.3 35 
(5.2-9.3) (2.1-5.3) (±O.2) (± 11) 
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These differences will be discussed in relation 
to the absorption, distribution, and metabo-
lism of Cs in each group. 
The absorption of Cs is variable, slow, and 
incomplete.28 .)} Peak concentrations in blood 
or plasma are observed one to eight hours 
after oral dosing, and the absorption half-life 
ranges from 0.6 to 2.3 hours.33•34Considerable 
variation has been observed in the peak con-
centrations of Cs in blood or plasma in recip-
ients of kidneys, hearts, and allogenic bone 
marrow grafts following oral therapy.28.35.36 
Following the ingestion of Cs, 600 mg, the 
peak serum HPLC concentration varied from 
240 to 1,250 ng/mL in six medical patients.34 
Renal transplant patients receiving 17.5 mg/ 
kg with breakfast had peak whole blood 
emi~; concentrations of 862 to 3,431 ng/ 
mL.J.7 
Marked variability in;;,:J:he extent of Cs 
absorption has been observe'ci in patients after 
organ transplantation. In adult kidney trans-
plant patients, the absolute bioavailability 
ranged from <5% to 89% with a mean of 
28%.18 The bioavailability of Cs in children 
following renal transplantation is 31 %,29 and 
following cardiac transplantation in adults, it 
is 35%.32 Adult liver transplant recipients 
have a m'ean bioavailability of 27% with a 
range of 8% to 60%.30 Pediatric liver trans-
plant patients absorb <5% to 19% of an orally 
administered dose of Cs in the immediate 
postoperative period. 31 
Orally administered Cs is poorly absorbed 
in the presence of intestinal disease.38•39 In 
bone marrow transplant patients, intestinal 
dysfunction may be mediated by chemoradia-
tion enteritis secondary to the conditioning 
regimen for marrow transplantation, acute 
graft-v- host disease of the intestine, or Can-
dida enteritis. Patients with greater than 500 
mL of diarrhea in 72 hours have a' signifi-
cantly lower area under the Cs serum concen-
tration curve v the time curve (AUC), indicat-
ing impaired drug absorption. 39 Impaired Cs 
absorption has also been noted in pediatric 
liver transplant patients with diarrhea.31 Tn 
these patients, intravenous (IV) Cs should be 
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administered to provide adequate immuno-
suppression. 
Coadministration of Cs with food may alter 
Cs bioavailability. A preliminary report36 sug-
gested that food delayed and impaired the 
absorption of Cs. We recently studied the 
effect of food on the absorption of Cs in renal 
transplant patients.28 A significant increase in 
the C m .. , Cmin' and AUC following Cs admin-
istration with food was observed compared 
with the fasted state. Additional studies are 
required to confirm this increase in the 
absorption of Cs with food following other 
transplant procedures (eg, liver transplanta-
tion, where no gallbladder is present) and to 
determine the effect of dietary composition on 
the absorption of Cs. 
ThE! ~sorption of fat and fat-soluble mate-
rial is impaired in patients with liver disease. 
Because Cs is fat soluble, its bioavailability is 
very low (12%) in patients with severe liver 
disease,40 as seen in Table 2. In the study by 
Venkataramanan et al,40 patients with a total 
serum bilirubin of <10 mg/IOO mL absorbed 
more than 5% of the administered drug, while 
the patients with a total serum bilirubin of 
>10 mg/IOO mL absorbed less than 5%. Sur-
gically induced cholestasis in dogs resulted in 
a decrease in Cs bioavailability from 23.5 ± 
9.7% before surgery to 7.4 ± 3.7% 1 week 
after surgery (unpublished observation). The 
poor bioavailability of Cs in patients with liver 
disease and in liver transplant patients during 
the immediate postoperative period may be 
related to the lack of sufficient bile and bile 
salts for Cs absorption. 
Similarly, the absorption of Cs is poor in 
liver transplant patients with external bile 
drainage via a T-tube. A significant increase 
in the trough blood concentration follows T-
tube clamping.41 Following clamping or 
removal of the T-tube, the rate and extent of 
absorption appears to increase as indicated by 
faster and higher peak blood concentrations. 42 
Comparative bioavailability studies ill the 
same liver transplant patients with and with-
out external bile drainage indicate a mean 
increase of 422% in the dose-normalized A UC 
, 
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following T-tube clamping (unpublished ob-
servation). This observation cannot be attrib-
uted to enterohepatic recycling oC Cs since 
< 1 % of a dose of Cs is excreted in the bile as 
unchanged drug. 43 Increased bile How into the 
gut following T-tube clamping is most likely 
responsible for the improved Cs absorption. 
Whenever external bile diversion is instituted 
or discontinued, adjustments in Cs dosage 
must be made. 
The oral administration of bile salts may be 
beneficial in patients with Cs malabsorption. 
In a preliminary study in six cirrhotic 
patients, the administration of 750 mg of 
chenodeoxycholic acid increased Cs oral 
absorption in four patients, did not affect 
absorption in one patient, and decreased Cs 
absorption in one patient (unpublished obser-
vation). Additional research into the solubili-
zation of Cs in the gut and its absorption will 
be necessary to optimally use pharmacologic 
facilitation of absorption. 
While improving absorption with increased 
bile flow is expected in liver transplant 
patients, improved absorption may also occur 
in renal transplant patients over the course of 
therapy. In kidney transplant patients, three-
to fivefold increases in oral bioavailability 
over time have also been noted.44 In one study, 
the mean bioavailability was 24.2 ...... '±'" 18.1 % 
during the first 2 weeks after kidney. trans-
plantation and increased to 50.2 ± 7.9% at 6 
to 12 months after transplantation.45 The 
exact nature of this improvement in absorp-
tion is not known. 
Limited numbers of studies of cS absorp-
tion have been performed in cardiK~c trans-
plant recipients, but no major problem has 
been noted with their drug absorption. The 
most significant pharmacokinetic variant that 
is shared by the cardiac transplant patients, 
children with severe heart disease prior to 
transplantation, and healthy volunteers is 
their small volume of distribution in compari-
Son with other transplant patients. The vol-
umes of distribution of 1.3, 0.9. and 1,j L/kg 
for the heart transplant,32 heart disease,26 and 
volunteer studies,22 respectively, are three- to 
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fivefold smaller than in renal and liver trans-
plant patients.28 ,3o This reduced volume of 
distribution will produce higher blood concen-
trations for any administered dose for the 
heart transplant recipient than for other 
transplant patients and may put the heart 
transplant recipient at increased risk of Cs 
toxicity. While hematocrit may partially 
explain these changes in distributional vol-
ume, other factors are most likely involved 
since the hematocrit varied from 29.8 to 63.6 
in our pretransplant congestive heart failure 
study,26 with little variation in the volume of 
distribution. 
The plasma protein binding of Cs appears 
to be highly variable among different patients 
and among different animal species. The 
unbound fraction of Cs in plasma from trans-
plant patients at 37°C ranges from 0.04 to 
0.17 and is significantly different than the 
unbound fraction in normal blood (unpub-
lished observation). The unbound fractions of 
Cs in dogs, humans, rats, and rabbits are 0.07, 
0.15, 0.19, and 0.33. respectively (unpub-
lished observation). These values appear to be 
related to the quantity of lipoproteins in the 
different species tested. 
Based on blood clearance estimates ob-
tained by HPLC, Cs can be classified as a low 
to intermediate clearance drug. Both its clear-
ance and elimination half-life are highly vari-
able among patients and are influenced by the 
type of transplant, age, disease state, and 
concurrent drug therapy. 
The elimination of Cs is influenced by the 
age of the patient. Pediatric patients appear to 
clear the drug more rapidly than adults on a 
body weight basis. The harmonic mean clear-
ance of Cs in a study involving 26 pediatric 
liver transplant patients was 8.4 mL/min/kg 
(range 1.9 to 13.9 mL/min/kg), which is 
higher than the clearance of Cs in adult liver 
transplant patients.31 Pediatric kidney trans-
plant recipients reportedly have a signifi-
cantly higher harmonic mean clearance of Cs 
(11.8 mLjminjkg; range, 9.8 to 15.5 mLj 
min/kg) compared with adult renal trans-
plant patients (5.7 mL/min/kg).29 Kahan et 
it., 
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al45 reported a higher Cs clearance from 
serum using radioimmunoassay (RIA) in 
patients less than 45 years of age compared 
with patients older than 45 years. The higher 
clearance in the pediatric population appears 
to be the result of more rapid removal of Cs 
from the body. Therefore, children may 
req)lire more frequent and larger doses of Cs 
per kilogram of body weight to achieve blood 
cqncentrations of the drug similar to those 
observed in adults. The kinetics of Cs have not 
been completely studied in the geriatric popu-
lation. Impairment in renal function with age 
should not contribute to any changes in Cs 
D~!D elimination, 
Since Cs is primarily eliminated by hepatic 
metabolism, its clearance is impaired in 
patients with liver disease. In eight patients 
with biopsy-proven cirrhosis, the harmonic 
mean clearance of Cs was 2.8 mL/min/kg 
(Table 2), which is approximately half the 
clearance value observed in kidney and liver 
transplant patients. The harmonic mean half-
life of Cs in these patients was prolonged to 
20.4 (range, 10.8 to 48.0) hours. Because of 
the marked influence of liver disease on Cs 
kinetics, blood concentration monitoring is 
essential in patients with severe liver dysfunc-
tion. 
Cs clearance is impaired in patients with 
congestive heart failure, presumably due to 
alterations in hepatic blood flow and hepatic 
function. Follow-up studies on patients after 
heart transplantation have shown an increase 
in drug clearance rate from pre- to posttrans-
plantation (2.1 to 3.9 and 2.0 to 7.2 mL/ 
min/kg in two patients).26 Heart transplant 
. recipients will have changing rates of Cs 
clearance until they can stabilize their cardiac 
output and hepatic function. 
Renal excretion is a minor pathway of 
elimination for Cs in humans and animals.35 
Less than 1%' of an administered dose is 
excreted unchanged in the urine. Approxi-
mately 6% of an administered dose of radioac-
tive Cs is excreted in the urine in 96 hours.35 
Therefore, changes in renal function alone 
should not alter Cs clearance. Additional sup-
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port-comes from the clearance rates in the two 
studies presented in Table 2 in pretransplant 
renal failure patients. 23,24 
A diurnal variation in the kinetics of Cs 
may occur in transplant patients. Eight 
patients (five male, three female) were stud-
ied approximately 2 weeks following cadav-
eric renal transplantation to examine varia-
tions wjthin a day (unpublished observation). 
On th~ day of the study after an overnight 
fast, each patient received an identical stan-
dard meal at 7:00 AM and 7:00 PM. At 8:00 AM 
and 8:00 PM, each patient received their nor-
mal dose of Cs (mean 11.9 ± 6.3 mg/kg/dose) 
mixed with 240 mL of chocolate milk. Blood 
samples were obtained in heparinized tubes 
everY'1v.40 hours for the 24-hour study period. 
Whole blood samples were analyzed by 
HPLC and RIA. The mean (±SD) area under 
the blood concentration time curve following 
the morning dose of cycIosporine was 9,455 
(±2,934) ng . h/mL, which was significantly 
higher (P < 0.01) than the AUC following the 
evening dose of Cs (7,604 ± 2,544). q'he peak 
concentration of Cs following the morning 
dose was 1,278 (±422) ng/mL compared with 
the peak of 920 (±413) following the evening 
dose (P < 0.01). There was no difference in 
the time to peak concentration (4.3 v 4.8 
hours), Cs trough concentration (266 v 264 
ng/mL), or elimination half-life (5.4 v 5.0 
hours) between the morning and evening 
doses of es. Diurnal variations in the pharma-
cokinetics of Cs in patients following cadav-
eric renal transplantation probably do occur 
in a manner similar to previous observations in 
liver transplant patients.2 
Several pharmacologic agents affect the 
clearance of Cs, and drug interactions are 
discussed elsewhere in this supplement. The 
most important inducers of Cs metabolism 
and elimination are phenytoin,14,36 phenobar-
bital,46 and rifampin.47 These agents can lower 
blood Cs concentrations and are associated 
with rejection episodes in transplant patients. 
The most potent inhibitors of Cs metabolism 
are ketoconazole48.49 and erythromycin, 50 As 
opposed to the slow onset of the metabolism 
I 
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inducers, ketoconazole and erythromycin can 
rapidly increase Cs blood concentrations, 
resulting in an increased risk of nephrotoxici-
ty. The reported interaction of high-dose 
methylprednisolone with Cs is questionable 
since no change in Cs clearance by HPLC can 
be detected during this steroid therapy.51 
SUMMARY 
Cs pharmacokinetic profiles using HPLC 
have aided in predicting necessary dosage 
alterations for specific groups of transplant 
patients. Additional information has been 
gained by HPLC profiles in non transplant 
subjects who are healthy or have a stable 
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disease state. The clinician now knows that 
liver disease not only impairs Cs elimination 
but may also have a pronounced effect upon 
drug absorption. While the cardiac failure 
patient may have reversible inhibition of Cs 
clearance, other factors may affect the distri-
bution of the drug to lower dosage require-
ments. Impaired renal function is not an 
impediment to Cs elimination, but malabsorp-
tion similar to that observed in liver and bone 
marrow transplant patients may still occasion-
ally complicate therapy. 
Pharmacokinetic information on Cs must 
be integrated into the complex care plan of a 
transplant patient to optimally utilize and 
monitor this pharmacologic agent. 
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